English
This article is from Indian Journal of Nephrology , volume 22 . Abstract We assessed the effect of renin angiotensin system blockade (RASB) in chronic kidney disease (CKD) of diverse etiology. Two hundred and sixty-five consecutive CKD patients attending our renal clinic, with estimated glomerular filtration rate (eGFR) of 20-70 ml/min/1.73m2 at baseline and a minimal follow-up of 1 year, were studied retrospectively. We devised a scoring system to quantify RASB, wherein the maximum dose of an agent recommended for control of hypertension was scored as 1. The renal endpoints studied were the rate of change in eGFR (ΔeGFR) and decline of eGFR>50%. The mean age was 48 ± 11.2 years and 69% were male. The mean duration of follow-up was 4 ± 2.7 years. The rate of ΔeGFR was –1.5 ± 5.0 ml/min/1.73 m2 per year in patients who received RASB (N=168) and –6.0 ± 5.4 in those who did not (N=97) (P 50% was 11.3% with RASB and 24.7% without (P=0.003). In a subgroup of patients who received RASB, the incidence of decline of eGFR >50% was 17.8% in the low-dose RASB group (N=84, RASB score 0.63 ± 0.38) and 4.8% in the high-dose group (N=84, RASB score 2.5 ± 0.7) (P=0.001). RASB was associated with s
Sign in with your free account to read, download EPUBs or listen.
Ebook · Retarding the progression of chronic kidney disease with renin angiotensin system blockade. · Limesh, M., Annigeri, R. A., Mani, M. K., Kowdle, P. C., Rao, B. Subba, Balasubramanian, S., Seshadri, R. · Internet Archive